Everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease.
Explore this paper's citation graph
Summary
Everolimus-eluting stents resulted in reduced rates of target-lesion failure at 1 year, results that were consistent in all patients except those with diabetes, in whom the results were nonsignificantly different.
- Type
- article
- Published
- 2010-05-04
- Cited by
- 901
- References
- 28
- Access
- Open access
- OpenAlex
- https://openalex.org/W2009589924
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:25951417
Keywords
Medicine, Paclitaxel, Everolimus, Coronary artery disease, Cardiology
References
- A randomised comparison of an everolimus-eluting coronary stent with a paclitaxel-eluting coronary stent:the SPIRIT II trial.
- Paclitaxel-eluting coronary stents in patients with diabetes mellitus: pooled analysis from 5 randomized trials.
- Impact of routine angiographic follow-up on the clinical benefits of paclitaxel-eluting stents: results from the TAXUS-IV trial.
- A randomized comparison of a durable polymer Everolimus-eluting stent with a bare metal coronary stent: The SPIRIT first trial.
- Paclitaxel-eluting or sirolimus-eluting stents to prevent restenosis in diabetic patients.
- Impact of sirolimus-eluting and Paclitaxel-eluting stents on outcome in patients with diabetes mellitus and stenting in more than one coronary artery.
- Randomized Comparison of Everolimus-Eluting and Paclitaxel-Eluting Stents: Two-Year Clinical Follow-Up From the Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions (SPIRIT) III Trial
- Incidence and Predictors of Drug-Eluting Stent Thrombosis During and After Discontinuation of Thienopyridine Treatment
- Differential phosphoinositide 3-kinase signaling: implications for PTCA?
- 2007 Focused update of the ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.
- Drug eluting and bare metal stents in people with and without diabetes: collaborative network meta-analysis
- Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents.
- Quantitative angiographic methods for appropriate end-point analysis, edge-effect evaluation, and prediction of recurrent restenosis after coronary brachytherapy with gamma irradiation.
- Offsetting Impact of Thrombosis and Restenosis on the Occurrence of Death and Myocardial Infarction After Paclitaxel-Eluting and Bare Metal Stent Implantation
- "Me-too" products--friend or foe?
- Endothelial cell recovery between comparator polymer-based drug-eluting stents.
- The long-term value of sirolimus- and paclitaxel-eluting stents over bare metal stents in patients with diabetes mellitus.
- Clinical End Points in Coronary Stent Trials: A Case for Standardized Definitions
- SPIRIT IV trial design: a large-scale randomized comparison of everolimus-eluting stents and paclitaxel-eluting stents in patients with coronary artery disease.
- A pooled analysis of data comparing sirolimus-eluting stents with bare-metal stents.
Cited by
- Comparison of titanium-nitride-oxide-coated stents with zotarolimus-eluting stents for coronary revascularization a randomized controlled trial.
- Resultados a largo plazo del stent farmacoactivo de zotarolimus según sus indicaciones de uso (aprobadas versus no aprobadas)
- A randomized comparison of platinum chromium-based everolimus-eluting stents versus cobalt chromium-based Zotarolimus-Eluting stents in all-comers receiving percutaneous coronary intervention: HOST-ASSURE (harmonizing optimal strategy for treatment of coronary artery stenosis-safety & effectiveness
- Two-year outcomes after first- or second-generation drug-eluting or bare-metal stent implantation in all-comer patients undergoing percutaneous coronary intervention: a pre-specified analysis from the PRODIGY study (PROlonging Dual Antiplatelet Treatment After Grading stent-induced Intimal hyperplas
- Randomized comparison of everolimus- and paclitaxel-eluting stents. 2-year follow-up from the SPIRIT (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System) IV trial.
- Twelve-month clinical outcomes of everolimus-eluting stent as compared to paclitaxel- and sirolimus-eluting stent in patients undergoing percutaneous coronary interventions. A meta-analysis of randomized clinical trials.
- Percutaneous coronary intervention with drug-eluting stent for unprotected left main trunk disease: safety and efficacy compared with bare metal stent. - Which coronary stent should be used for the left main trunk disease? BMS or DES? (DES side)-.
- Outcomes after unrestricted use of everolimus-eluting stent compared to paclitaxel- and sirolimus-eluting stents.
- Predictors of early and late outcomes after everolimus and paclitaxel-eluting coronary stents.
- Long-term comparison of everolimus- and sirolimus-eluting stents in patients with acute coronary syndromes.
- Comparison of outcomes in patients with versus without diabetes mellitus after revascularization with everolimus- and sirolimus-eluting stents (from the SORT OUT IV trial).
- Clinical ResearchInterventional CardiologyClinical Outcome Following Stringent Discontinuation of Dual Antiplatelet Therapy After 12 Months in Real-World Patients Treated With Second-Generation Zotarolimus-Eluting Resolute and Everolimus-Eluting Xience V Stents: 2-Year Follow-Up of the Randomized TW
- Everolimus- versus sirolimus-eluting stents for the treatment of unprotected left main coronary artery stenosis (results from the EXCELLENT registry).
- Incidence and predictors of stent thrombosis: a single-centre study of 5,833 consecutive patients undergoing coronary artery stenting.
- Third-generation zotarolimus-eluting and everolimus-eluting stents in all-comer patients requiring a percutaneous coronary intervention (DUTCH PEERS): a randomised, single-blind, multicentre, non-inferiority trial.
- Predicting target vessel revascularization in older patients undergoing percutaneous coronary intervention in the drug-eluting stent era
- Optimal Choice of Coronary Revascularization and Stent Type in Diabetic Patients with Coronary Artery Disease
- Everolimus-eluting versus sirolimus-eluting stents in patients undergoing percutaneous coronary intervention: the EXCELLENT (Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting) randomized trial.
- Who Is Thrombogenic: The Scaffold or the Doctor? Back to the Future!
- Cost‐effectiveness of percutaneous coronary intervention with cobalt‐chromium everolimus eluting stents versus bare metal stents: Results from a patient level meta‐analysis of randomized trials
Related papers
- ФОРМИРОВAНИЕ ГОТОВНОСТИ БУДУЩИХ ПЕДAГОГОВ К ОРГAНИЗAЦИИ РAБОТЫ ПО РAЗВИТИЮ ВAЛЕОЛОГИЧЕСКОЙ КУЛЬТУРЫ ШКОЛЬНИКОВ
- चितलवाना पंचायत समिति में मानव गरीबी सूचकांक - 2016 ( à¤à¤• गà¥à¤°à¤¾à¤® सà¥à¤¤à¤°à¥€à¤¯ à¤à¥Œà¤—ोलिक अधà¥à¤¯à¤¯à¤¨ )
- A GEOMETRIC MEAN IN THE FURUTA INEQUALITY
- Everolimus-Induced Interstitial Pneumonitis in a Patient with Metastatic Renal Cell Carcinoma: a Case Report